Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T. Hay AE, et al. Among authors: murugesan a. Leuk Lymphoma. 2016;57(6):1463-6. doi: 10.3109/10428194.2015.1091927. Epub 2015 Oct 15. Leuk Lymphoma. 2016. PMID: 26376958 Clinical Trial. No abstract available.
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.
Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T. Han M, et al. Among authors: murugesan a. Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. Epub 2016 Jun 23. Blood. 2016. PMID: 27338095 Free article. No abstract available.
Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10.
Grieve S, Ding K, Moore J, Finniss M, Ray A, Lees M, Hossain F, Murugesan A, Agar J, Acar C, Taylor J, Shepherd FA, Reiman T. Grieve S, et al. Among authors: murugesan a. ESMO Open. 2020 Mar;5(2):e000679. doi: 10.1136/esmoopen-2020-000679. ESMO Open. 2020. PMID: 32220948 Free PMC article.
Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy.
Grieve S, Puvvada N, Phinyomark A, Russell K, Murugesan A, Zed E, Hassan A, Legare JF, Kienesberger PC, Pulinilkunnil T, Reiman T, Scheme E, Brunt KR. Grieve S, et al. Among authors: murugesan a. Nanomedicine (Lond). 2021 Oct;16(24):2175-2188. doi: 10.2217/nnm-2021-0076. Epub 2021 Sep 22. Nanomedicine (Lond). 2021. PMID: 34547916 Free article.
Growth phase-dependent ribonucleic acid production dynamics.
Shoaib M, Murugesan A, Devanesan S, AlSalhi MS, Kandhavelu M. Shoaib M, et al. Among authors: murugesan a. Int J Biol Macromol. 2024 May 19;270(Pt 2):132457. doi: 10.1016/j.ijbiomac.2024.132457. Online ahead of print. Int J Biol Macromol. 2024. PMID: 38772467
Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations.
Selvavinayagam ST, Sankar S, Yong YK, Murugesan A, Suvaithenamudhan S, Hemashree K, Rajeshkumar M, Kumaresan A, Pandey RP, Shanmugam S, Arthydevi P, Kumar MS, Gopalan N, Kannan M, Cheedarla N, Tan HY, Zhang Y, Larsson M, Balakrishnan P, Velu V, Byrareddy SN, Shankar EM, Raju S. Selvavinayagam ST, et al. Among authors: murugesan a. medRxiv [Preprint]. 2024 Apr 19:2024.04.16.24305882. doi: 10.1101/2024.04.16.24305882. medRxiv. 2024. PMID: 38699322 Free PMC article. Preprint.
153 results